Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2Qi77Ib
via IFTTT